Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure…
Continue Reading-
Attgeno appoints Björn Westberg as CFO
Attgeno appoints Björn Westberg as CFO Jul 08, 2021 05:00 UTC Attgeno AB announces today…
Continue Reading -
SAGA Diagnostics raises €10.5 million
SAGA Diagnostics raises SEK 106 million (€10.5 million)...
Continue Reading -
Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round
Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company…
Continue Reading -
Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248
Stockholm, Sweden, June 14 2021 Gesynta Pharma announces significant progress across development program for first-in-class…
Continue Reading -
Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of…
Continue Reading -
Join Hadean Ventures!
April 30, 2021 Hadean Ventures is a fast-growing life science fund manager that invests in…
Continue Reading -
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin®
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® in the Ongoing…
Continue Reading -
Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies
Archamps, France, 24 March 2021 Step Pharma, a biotech company developing novel drugs for oncology…
Continue Reading -
Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial
Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial…
Continue Reading